This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BI 44847

Boehringer Ingelheim GmbH

Drug Names(s): BI44847

Description: BI 44847 is an oral, sodium-dependent glucose transporter-2 inhibitor (SGLT-2 inhibitor). SGLT-2 inhibitors express their therapeutic effect mainly by eliminating excess blood glucose via the urine.

Deal Structure: BI 44847 was in-licensed by Boehringer Ingelheim from Ajinomoto. Boehringer is the worldwide exclusive licensee for the rights to develop, manufacture and sell the drug. Ajinomoto retains a co-promotion right in japan.

Partners: Ajinomoto Pharmaceuticals Co., Ltd.

BI 44847 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug